CNBCLean R·
Eli Lilly stock edges higher as company plans nearly $4 billion in vaccine deals
The deals are part of Eli Lilly’s effort to expand into infectious disease research and development.
Read at CNBC →
Business · 1 sources covering this
Eli Lilly stock edges higher as company plans nearly $4 billion in vaccine deals
The deals are part of Eli Lilly’s effort to expand into infectious disease research and development.
Coverage spectrum
0 L · 0 C · 1 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/f97b706bfc81c9d0ca2d6f5254e200b4797dc153" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Eli Lilly stock edges higher as company plans nearly $4 billion in vaccine deals"></iframe>
